GSK938890A | CAS#913640-57-0

MedKoo Cat#: 555395 | Name: GSK938890A

Description:

WARNING: This product is for research use only, not for human or veterinary use.

GSK938890A is a Highly Potent Protein Kinase C-Related Kinase 1 Inhibitor.

Chemical Structure

GSK938890A

CAS#913640-57-0

Theoretical Analysis

MedKoo Cat#: 555395

Name: GSK938890A

CAS#: 913640-57-0

Chemical Formula: C23H25N7O3

Exact Mass: 447.2019

Molecular Weight: 447.50

Elemental Analysis: C, 61.73; H, 5.63; N, 21.91; O, 10.73

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

913640-57-0 913640-58-1 (R-Isomer)

Synonym

GSK938890A; GSK-938890A; GSK 938890A; CHEMBL1096626;

IUPAC/Chemical Name

(S)-4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-6-(2-amino-2-phenylethoxy)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl)-2-methylbut-3-yn-2-ol

InChi Key

NPRGDRYIMFLLIG-OAHLLOKOSA-N

InChi Code

InChI=1S/C23H25N7O3/c1-4-30-17-12-18(32-13-15(24)14-8-6-5-7-9-14)26-16(10-11-23(2,3)31)19(17)27-22(30)20-21(25)29-33-28-20/h5-9,12,15,31H,4,13,24H2,1-3H3,(H2,25,29)/t15-/m1/s1

SMILES Code

CCN1C2=CC(=NC(=C2N=C1C3=NON=C3N)C#CC(C)(C)O)OC[C@H](C4=CC=CC=C4)N

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 447.50 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1. In Silico Screen and Structural Analysis Identifies Bacterial Kinase Inhibitors which Act with β-Lactams To Inhibit Mycobacterial Growth By Wlodarchak, Nathan; Teachout, Nathan; Beczkiewicz, Jeffrey; Procknow, Rebecca; Schaenzer, Adam J.; Satyshur, Kenneth; Pavelka, Martin; Zuercher, William; Drewry, David; Sauer, John-Demian; et al. From Molecular Pharmaceutics (2018), 15(11), 5410-5426. 2. Identification of Highly Potent Protein Kinase C-Related Kinase 1 Inhibitors by Virtual Screening, Binding Free Energy Rescoring, and in vitro Testing By Slynko, Inna; Schmidtkunz, Karin; Rumpf, Tobias; Klaeger, Susan; Heinzlmeir, Stephanie; Najar, Abdulkarim; Metzger, Eric; Kuster, Bernhard; Schuele, Roland; Jung, Manfred; et al. From ChemMedChem (2016), 11(18), 2084-2094. 3. Use of kinase inhibitors to increase the susceptibility of gram positive bacteria to β-lactam antibiotics. By Striker, Robert Todd; Sauer, John-Demian; Wlodarchak, Nathan. From U.S. Pat. Appl. Publ. (2015), US 20150307495 A1 20151029. | 4. Aminofurazans as potent inhibitors of AKT kinase. By Rouse, Meagan B.; Seefeld, Mark A.; Leber, Jack D.; McNulty, Kenneth C.; Sun, Lihui; Miller, William H.; Zhang, Shu Yun; Minthorn, Elisabeth A.; Concha, Nestor O.; Choudhry, Anthony E.; et al From Bioorganic & Medicinal Chemistry Letters (2009), 19(5), 1508-1511. 5. Imidazopyridinyl compounds as inhibitors of AKT activity and their preparation, pharmaceutical compositions and use in the treatment of cancer and arthritis. By Heerding, Dirk A.; Rouse, Meagan B.; Seefeld, Mark Andrew. From PCT Int. Appl. (2006), WO 2006113837 A2 20061026.